Book a Call
Welcome to our CERES Regulatory Services scheduling page. Every case is unique and personal, so let’s talk. This meeting will be conducted with a Senior Regulatory Consultancy Experts.
Fastest FDA Approvals
Product: BLINCYTO®(blinatumomab)
Year Approved: 2014
FDA Designation: Breakthrough therapy
Months to Approval: 2.5
Year Approved: 2014
FDA Designation: Breakthrough therapy
Months to Approval: 2.5
Product: ICLUSIG® (ponatinib)
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 2.6
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 2.6
Product: JEVTANA® (cabazitaxel)
Year Approved: 2010
FDA Designation: Priority review
Months to Approval: 2.6
Year Approved: 2010
FDA Designation: Priority review
Months to Approval: 2.6
Product: SPINRAZA® (nusinersen)
Year Approved: 2016
FDA Designation: Priority review
Months to Approval: 3
Year Approved: 2016
FDA Designation: Priority review
Months to Approval: 3
Product: ALECENSA® (alectinib)
Year Approved: 2015
FDA Designation: Priority review
Months to Approval: 3.1
Year Approved: 2015
FDA Designation: Priority review
Months to Approval: 3.1
Product: TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor)
Year Approved: 2019
FDA Designation: Breakthrough therapy
Months to Approval: 3.1
Year Approved: 2019
FDA Designation: Breakthrough therapy
Months to Approval: 3.1
Product: XTANDI® (enzalutamide)
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 3.3
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 3.3
Product: KALYDECO® (ivacaftor)
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 3.5
Year Approved: 2012
FDA Designation: Priority review
Months to Approval: 3.5
Product: ZELBORAF® (vemurafenib)
Year Approved: 2011
FDA Designation: Priority review
Months to Approval: 3.6
Year Approved: 2011
FDA Designation: Priority review
Months to Approval: 3.6
Product: ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Year Approved: 2019
FDA Designation: Breakthrough therapy
Months to Approval: 3.7
Year Approved: 2019
FDA Designation: Breakthrough therapy
Months to Approval: 3.7
Previous
Next
Explore our services
Innovative Products
Navigating the intricate landscape of Innovative Products Regulatory compliance to ensure seamless market entry and sustained success. Expert guidance provided.
Cell Therapy
Revolutionize healthcare with cutting-edge Cell Therapy. Harness the power of cellular advancements for groundbreaking treatments, transforming the future of medicine.
Gene Therapy
Unlock the potential of personalized medicine through groundbreaking Gene Therapy. Pioneering genetic advancements for targeted, transformative treatments, reshaping the landscape of healthcare.